Ilumya 100 mg prefilled syringe (PFS) contains the active substance Tildrakizumab, a humanized monoclonal antibody used for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Tildrakizumab works by selectively targeting interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses that contribute to the development of psoriasis. By inhibiting IL-23, Ilumya helps reduce inflammation, plaque formation, and skin symptoms associated with psoriasis.

Do not use Ilumya if you are allergic to Tildrakizumab or any of the ingredients of this medicine. Inform your doctor before starting treatment if you have active or chronic infections, tuberculosis, or a weakened immune system. Patients should also be evaluated for tuberculosis prior to initiating therapy.

Ilumya is indicated for:

• Moderate to severe plaque psoriasis
• Patients eligible for systemic therapy or phototherapy
• Long-term management of chronic inflammatory skin conditions

This therapy is especially beneficial for patients who do not respond adequately to conventional treatments.

Ilumya works by selectively targeting and inhibiting interleukin-23 (IL-23), a cytokine involved in inflammatory immune responses.

By blocking IL-23, Ilumya helps the following:

• Reduce inflammation in the skin
• Slow down excessive skin cell production
• Decrease plaque thickness and scaling
• Improve overall skin appearance

This targeted mechanism helps provide sustained symptom relief with fewer systemic effects compared to traditional therapies.

Ilumya injection should be administered under the supervision of a healthcare professional.

• Given as a subcutaneous injection

• Recommended dose: 100 mg at week 0, week 4, and every 12 weeks thereafter

• Injection sites include thigh, abdomen, or upper arm

Do not self-administer unless properly trained by a healthcare provider.

Common side effects include:

• Upper respiratory tract infections

• Injection site reactions

• Diarrhea

• Headache

• Back pain

Serious side effects may include:

• Severe infections

• Hypersensitivity reactions

Seek medical attention if serious symptoms occur.

Inform your healthcare provider about all medicines you take, including prescription drugs, over-the-counter medications, vitamins, and herbal supplements.

Particular caution is required with:

• Immunosuppressive agents

• Live vaccines (should be avoided during treatment)

• Other biologic therapies

Ilumya may increase the risk of infections when used with other immunosuppressive medicines.

• Store in a refrigerator at 2°C to 8°C

• Do not freeze

• Keep the prefilled syringe in the original carton to protect from light

• Do not shake the syringe

• Keep out of reach of children

• Patients should be screened for tuberculosis before starting treatment

• Avoid live vaccinations during therapy

• Monitor for signs of infection throughout treatment

• Follow the prescribed dosing schedule strictly

• Inform your healthcare provider if you experience any unusual symptoms

Infections (Caution)

Ilumya may increase the risk of infections. Inform your doctor if you develop signs of infection such as fever, cough, or fatigue.

Vaccination (Consult Your Doctor)

Avoid live vaccines during treatment with Ilumya.